A recent review published in The BMJ has shed light on the effectiveness of obesity drugs concerning both quality of life and cardiovascular health. The analysis, which combined data from multiple studies, confirms that several contemporary obesity medications, including semaglutide and tirzepatide, are capable of delivering considerable and clinically meaningful weight reduction for patients.
However, the interpretation of the review's findings, particularly regarding quality of life, has prompted expert discussion. Dr. Hamid Merchant, Head of the Department for Biosciences at the University of East London, cautioned that while improvements in quality of life were observed, they did not consistently surpass a pre-established threshold for what the authors considered a 'clinically important difference' on a generic quality-of-life scale. He emphasised that this should not be misconstrued as evidence that patients gain no benefit, highlighting that the chosen 10-point threshold on the SF-36 scale is a judgement-based criterion and different methodologies could yield varied interpretations.
Crucially, the review also presented positive news regarding cardiovascular outcomes for some of these medications. Injectable semaglutide was associated with reductions in all-cause mortality, myocardial infarction (heart attack), and heart failure. Similarly, tirzepatide was linked to a decreased risk of heart failure. While much of this cardiovascular evidence stems from trials conducted in higher-risk populations, and many obesity trials are not primarily designed for long-term cardiovascular outcomes, these findings suggest important benefits beyond just weight loss.
Dr. Merchant further stressed that the significant weight reductions, often approaching 10-15% with certain treatments, have broader health implications. These include positive effects on glycaemic control, sleep apnoea, mobility, symptoms of osteoarthritis, metabolic dysfunction-associated steatotic liver disease, and future cardiometabolic risk. These wider benefits, he argued, are not always sufficiently highlighted when focusing solely on quality of life metrics.
The review underscores the complexity of assessing the overall impact of obesity drugs. Experts advocate for personalised treatment decisions that carefully weigh the benefits, potential risks, patient preferences, and the practicalities of treatment. This approach should always be integrated with ongoing lifestyle interventions, aligning with broader NHS guidelines that promote a holistic strategy for managing obesity and its associated health conditions.